News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Nanobiotix Selected to Present at Future Leaders in the Biotech Industry Conference



3/19/2013 11:37:25 AM

Paris, France, March 19, 2013 – Nanobiotix (Euronext: NANO), the oncology focused nanomedicine company, announces that its co-founder and CEO, Laurent Levy, has been invited to give a Company Presentation at the 20th Annual Future Leaders in the Biotech Industry Conference in New York.

The Nanobiotix presentation is scheduled on Friday 5 April 2013 at 10:30 am ET in room 508 at the Millennium Hotel in New York, NY. Laurent Levy will provide an overview of the Company’s strategy, technology and pipeline including its NanoXray technology, which has been developed to enhance radiotherapy energy to destroy tumor cells while not causing additional damage to the healthy surrounding tissue. Following the presentation there will be a breakout session from 11:00am – 11:30am ET, in room 507.

The conference, which is co-hosted by BioCentury and Thomson Reuters, invites companies in key therapeutic areas to present a 25-minute company overview to leading portfolio managers, bankers and analysts. Nanobiotix is one of the few European Companies invited to present.

For more information about the conference, please visit: http://www.biocentury.com/conferences/futureleaders

About NANOBIOTIX

Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy and brachytherapy treatments and are applicable to treat a wide variety of cancers via multiple routes of administration. Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma. The company has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia. The company is based in Paris, France.

For more information, please visit www.nanobiotix.com

For more information, please contact:

Nanobiotix

Laurent Levy

CEO

+33 (0)1 40 26 07 55

laurent.levy@nanobiotix.com

NewCap.

Financial communication

and investors relations Louis-Victor Delouvrier / Emmanuel Huynh

+33 (0)1 44 71 98 53

lvdelouvrier@newcap.fr

Yucatan

Media relations (France)

Annie-Florence Loyer/ Nadège Le Lezec

+33 (0)1 53 63 27 27 / +33 (0)6 88 20 35 59

afloyer@yucatan.fr

College Hill

Media relations (Europe excl. France)

Melanie Toyne Sewell / Anastasios Koutsos / Donia Al Saffar

+44 (0) 207 457 2020

nanobiotix@collegehill.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES